DRMA - CONSENSUS CO - Dermata Therapeutics

The price visualization on GURU.Markets for Dermata Therapeutics (DRMA), which assists in the basic asset valuation, demonstrates the dynamics of a company with a consensus forecast of 3.99. The business relies on AI-driven screening of dermatological formulations, replacing manual labor with algorithms. Stability is guaranteed by a fully staffed team of research biologists and the targeted hiring of regulatory specialists, while the environmental sustainability of substance synthesis is ensured through the implementation of zero-waste production cycles.

The consensus forecast represents the arithmetic mean of target prices from leading investment banks, reflecting aggregated market expectations for the asset's value. By analyzing the history of the consensus target for the security, an investor sees the current value of 3.99, which in the case of Dermata Therapeutics (DRMA) is supported by a stable operational backdrop in the US and the absence of trade barriers for humanitarian dermatological drugs.